Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. AZN has several negative signals and is within a falling trend, so we believe it will perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Our analysis conclusion for this stock is a Strong Sell candidate.
AZN stock price ended at $70.2 on Thursday, after rising0.75%
The AstraZeneca PLC stock price increased by 0.75% on the last trading day (22 May 2025), rising from 70.96 to 69.68. Throughout the last trading session, the stock experienced a fluctuation of 2.03% , ranging from a day low of $69.57 to a day high of 70.98. The price has declined in 4 of the last 10 days, resulting in a total change of -0.56% during this period. On the last day, trading volume increase by 98.36K shares, with the rising prices. This could serve as an early warning, indicating that risk may slightly increase in the coming days. In total, 4.39M shares were traded, amounting to approximately 308.99M.
AZN Technical Signals
AZN(AstraZeneca PLC Corp) has 1 buy signal and 2 sell signals now. The current trend is consolidation starting from 2025-05-12. The total price change during this trend is +1.06%. Recently, the price has decreased with an increase in volume, indicating a strong bearish signal. The average turnover of AZN over the last 5 trading days is 328.31M. Overall, the technical indicator signals lean more toward a Neutral outlook in the mid-term.
AZN Moving Average Analysis
AstraZeneca PLC's overall moving average trend leans more bearish as of Friday, May 23, 2025, with 3 negative signals and 1 positive signal. In the mid-term, the SMA_20 being below the SMA_60 signals a strong bearish trend. There will be some resistance from the lines at $71.48642666666667, and $73.32766666666667. A break-up above any of these levels will issue buy signals. There will be some support from the lines at $65.52890666666666, and $63.68766666666666. A break-down below any of these levels will issue sell signals.
AZN Short Selling Analysis
The short sale ratio of AstraZeneca PLC(AZN) as of 16 May 2025 is 12.02%, rising from last trading day. With increasing price from 67.96 to 68.81. The short sell activity indicate that short sellers may be anticipating a price reversion.
Technical Signal
Technical Signals Summary
Sell
2
Buy
1
Moving Average
Swing
Positive
Stock Price Above SMA_5
Short Term
Negative
SMA_5 Below SMA_20
Mid Term
Negative
SMA_20 Below SMA_60
Long Term
Negative
SMA_60 Below SMA_200
Short Selling
Close Price
Short Sale Ratio
Short Sale Volume
1 Bullish Signals
1 Bullish Signals
When Value satisfies Signal, Indicator signals Bullish
Indicators
Signal
Value
Meaning
Awesome Oscillator (5, 34)
AO_5_34 > 0
0.365
Bullish
2 Bearish Signals
2 Bearish Signals
When Value satisfies Signal, Indicator signals Bearish
Indicators
Signal
Value
Meaning
Momentum (10 days)
MOM_10 < 0
-0.39
Bearish
Moving Average Convergence Divergence (12, 26, 9)
MACD_12_26_9 < 0
-0.311
Bearish
AZN Price Prediction & Forecast by Similar Chart Analysis
Based on historical patterns and backtesting of stocks with similar movements to AstraZeneca PLC(AZN), our algorithm predicts AZN's 1-month price at $54.06, with an -21.44%downwardshift. Using a similarity score up to 93.73%and other factors, This forecast updates weekly, adjusting for significant deviations.
Similar Chart
The price prediction chart for AstraZeneca PLC (AZN.O) stock, as of Sunday, May 18, 2025 , forecasts a -21.44% change over the next month, based on its high correlation with ADAP.O stock patterns. The similarity between their price movements over the analyzed periods is 93.73%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
AZN
No Data
ADAP
Down: -21.44%Similarity: 93.73%
Name
Similarity
Up/Down
ADAP.O
93.73%
-21.44%
L.N
92.47%
+5.10%
PWOD.O
92.10%
+0.97%
MS.N
92.08%
+8.22%
PPG.N
92.05%
+11.06%
CNS.N
91.95%
+6.46%
CRGY.N
91.90%
+15.90%
ZIM.N
91.87%
+18.08%
TPST.O
91.87%
-10.90%
AZN Seasonality Analysis
Based on AZN's historical stock price data across all years, the probability of a positive return in May is63.64%, suggesting it maybe an ideal month to invest in AZN. In contrast,Marchoffers the highest probability of positive returns at81.82%, making it a potentially strong month for investment.
However, this is only a prediction based on one method, and a comprehensive assessment of the stock's future trend should consider additional factors. Our final stock price commentary incorporates three main evaluation dimensions: technical signals, Moving Average trends, and similar chart pattern matching, with the first two dimensions carrying the primary weight to ensure a more robust and accurate forecast.
Monthly Seasonality
The radar chart shows that buying AstraZeneca PLC (AZN.O) stock in March has the highest probability of a positive return (81.82%), while June has the lowest probability (30.00%).
Performance Seasonality
The chart shows AstraZeneca PLC. (AZN)'s annual stock price return for the past three years, helping you analyze price trends and identify recurring trends on an annual basis.
People Also Watch
FAQ
Should I buy AstraZeneca PLC (AZN.O) stock?
Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. AZN has several negative signals and is within a falling trend, so we believe it will perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Our analysis conclusion for this stock is a Strong Sell candidate.
Which months have the highest win rate for buying AstraZeneca PLC (AZN.O) stock in a year?
The radar chart shows that buying AstraZeneca PLC (AZN.O) stock in March has the highest probability of a positive return (81.82%), while June has the lowest probability (30.00%).
How has AstraZeneca PLC. (AZN)'s stock price performed over the past three years?
AZN's stock price fell by -0.80% in 2023,decreased by -2.14% in 2024, and went up by 6.56% in 2025.
Which bull technical signals does AZN have?
Bullish technical signals of AZN include: AO_5_34 > 0.
Is AZN a buy based on overall technical signals summary?
AZN has 1 buy signals and 2 sell signals now. Overall the technical rating for AZN is Neutral . Note that market conditions change all the time. In addition to technical ratings, keep an eye on the Valuation Level of AZN.
What is the trend of AstraZeneca PLC (AZN)'s moving average?
AstraZeneca PLC's overall moving average trend leans more bearish as of May 23 2025, with 3 negative signals and 1 positive signal.
What is price prediction for AZN stock next month?
The price prediction chart for AstraZeneca PLC (AZN.O) stock, as of May 18 2025, forecasts a -21.44% change over the next month, based on its high correlation with ADAP stock patterns. The similarity between their price movements over the analyzed periods is 93.73%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
What is price prediction 2025 for AZN Stock?
AstraZeneca (AZN) stock is predicted to reach **$72 by year-end 2025**, driven by strong pipeline momentum and positive trial results. The stock currently trades at $68.77, with neutral RSI levels and stabilizing MACD, suggesting moderate upside potential.
What is price prediction 2030 for AZN Stock?
AstraZeneca (AZN) is expected to reach a price of **$120 by 2030**, driven by its robust pipeline, strategic collaborations, and positive investor sentiment.
- **Strong Pipeline and Growth Prospects**: AstraZeneca has a diverse and innovative pipeline, particularly in oncology and rare diseases, which positions it for sustained growth.
- **George Soros Investment**: Soros Fund Management's significant investment in AZN reflects confidence in its long-term potential, suggesting a bullish outlook.
- **Collaboration with Merck**: The success of Keytruda in ovarian cancer trials and AZN's partnership with Merck on Lynparza highlight its strength in oncology.
These factors, combined with its reasonable valuation (forward P/E of 14.67), support the $120 price target by 2030.